Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 4/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 15/20 | 0.54 |
| ▸ | PAK3 | O75914 | 1/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12004739 | 1.00 | CXCR3 (0.55) | CXCR3EPHX2PAK3PAK1PAK2 | |
| SCHEMBL6863633 | 1.00 | CXCR3 (0.55) | CXCR3EPHX2PAK3PAK1PAK2 | |
| SCHEMBL6863248 | 0.93 | CXCR3 (0.51) | CXCR3EPHX2PAK3PAK1PAK2 | |
| SCHEMBL12005295 | 0.85 | CXCR3 (0.46) | CXCR3EPHX2PAK3PAK1PAK2 | |
| SCHEMBL12005297 | 0.85 | CXCR3 (0.46) | CXCR3EPHX2PAK3PAK1PAK2 | |
| SCHEMBL12005445 | 0.85 | CXCR3 (0.46) | CXCR3EPHX2PAK3PAK1PAK2 | |
| SCHEMBL6863225 | 0.84 | EPHX2 (0.47) | EPHX2 | |
| SCHEMBL4279470 | 0.83 | EPHX2 (0.45) | CXCR3EPHX2PAK1 | |
| SCHEMBL4279471 | 0.83 | EPHX2 (0.45) | CXCR3EPHX2PAK1 | |
| SCHEMBL12015290 | 0.83 | EPHX2 (0.45) | CXCR3EPHX2PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | CXCR3 2678/4885EPHX2 3610/4885PAK3 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.